Abstract
Background: Insulin and insulin-like growth factor I (IGF-I) are important mitogens in vitro and in vivo. It has been hypothesized that these factors may play an important role in the development of breast cancer. Methods: A case-control study comparing plasma insulin levels in 99 premenopausal women with newly diagnosed node-negative invasive carcinoma of the breast and 99 age-matched controls with incident biopsied non-proliferative breast disease (NP) was conducted. Women with known diabetes were excluded. Results: For the entire study group, mean age was 42.6 ± 5.1 years and mean weight was 62.9 ± 10.3 kg. After adjustment for age and weight, elevated insulin levels were significantly associated with breast cancer, Odds Ratio (OR) for women in the highest insulin quintile versus the lowest quintile=2.83 (95% Confidence Interval [CI] 1.22–6.58). There were no statistically significant differences between cases and controls for IGF-I and IGFBP-1 levels. However, after adjustment for age, the association between plasma levels of insulin-like growth factor binding protein 3 (IGFBP-3) and breast cancer approached statistical significance; OR for highest quintile versus lowest quintile of IGFBP-3 being 2.05 (95% CI, 0.93–4.53). All results were independent of diet and other known risk factors for breast cancer. Conclusion: Circulating insulin levels and possibly IGFBP-3 levels are elevated in women with premenopausal breast cancer. This association may reflect an underlying syndrome of insulin resistance that is independent of obesity.
Similar content being viewed by others
References
Bruning PF, Bonfrer JMG, Van Nooyrd PAH, Hart AAM, De Jong-Bakker M, Nooijen WJ: Insulin resistance and breast cancer risk. Int J Cancer 52: 511–516, 1992
Repert RW: Breast cancer: Relation to thyroid disease and diabetes. J Michigan State M Soc 52: 1315–1320, 1952
Lancaster HO, Maddox JK: Diabetic mortality in Australia. Austr Ann Med 7: 145–151, 1958
Unger C, Rageth JC, Wyss P: Risk factors in breast carcinoma. J Suisse Med 121: 30–36, 1991
Glicksman AS, Myers WPL, Rawson RW: Diabetes mellitus and carbohydrate metabolism in patients with cancer. Med Clin N Amer 40: 887–900, 1956
Muck BR, Trotnow S, Hommel G: Cancer of the breast, diabetes and pathological glucose tolerance. Arch Gynak 220: 73–81, 1975
Barker BE, Fanger H, Farnes P: Human mammary slices in organ culture. I. Methods of culture and preliminary observations on the effects of insulin. Exp Cell Res 35: 437–448, 1964
Elias JJ, Armstrong RC: Hyperplastic and metaplastic responses of human mammary fibroadenomas and dysplasias in organ culture. J Natl Cancer Inst 51: 1341–1343, 1973
Dideriksen LH, Jorgensen LN, Drejer K: Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 41 (Suppl 1): 143A, 1992
Giogino F, Belfiore A, Milazzo G, Costantino A, Maddux B, Whittaker J et al.: Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol 5: 452–459, 1991
Kaleko M, Rutter WJ, Miller AD: Overexpression of the human insulinlike growth factor I receptor promotes liganddependent neoplastic transformation. Mol Cell Biol 10: 464–473, 1990
Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C et al.: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503–2512, 1986
Goodwin PJ, Boyd NF, Hanna W, Hartwick W, Murray D, Qizilbash A, Redwood S, Hood N, Del Guidice NE, Sidlofsky S, McCready D, Wilkinson R, Mahoney L, Connelly P, Page D: Elevated levels of plasma triglycerides are associated with premenopausal breast cancer risk. Nutr Cancer 27: 284–292, 1997
Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312: 146–151, 1985
Block G, Hartman A, Dresser CM, Carroll MD, Gannon J, Gardner L: A data based approach to diet questionnaire design and testing. Am J Epidemiol 86: 453–469, 1986
Ezzat S, Song-Guang R, Braunstein GD, Melmed S: Octreotide stimulates insulin-like growth factor binding protein-1: A potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab 75: 1459–1463, 1992
SAS Institute Inc.: SAS/STAT user's guide, version 6.09. Cary, NC: SAS Institute Inc. (1989)
Hill DJ, Milner RDG: Insulin as a growth factor. Pediatr Res 19: 879–886, 1985
Straus DS: Growth-stimulatory actions of insulin in vitro and in vivo. Endocrinol Rev 5: 356–369, 1984
Straus DS: Effects of insulin on cellular growth and proliferation. Life Sci 29: 2131–2139, 1981
Webster NJG, Resnik JL, Reichart DB, Strauss B, Haas M, Ceely BL: Repression of the insulin receptor promotor by the tumor suppressor gene product p53; a possible mechanism for receptor overexpression in breast cancer. Cancer Res 36: 2781–2788, 1996
Zapf J, Schoenle E, Froesch ER: Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur J Biochem 87: 285–296, 1978
Lammers R, Gray A, Schlessinger J, Ullrich A: Differential signalling potential of insulin-and IGF-I receptor cytoplasmic domains. EMBO J 8: 1369–1375, 1989
Holdaway IM, Friesen HG: Hormone binding by human mammary carcinoma. Cancer Res 37: 1946–1952, 1977
Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L et al.: Elevated insulin receptor content in human breast cancer. J Clin Invest 86: 1503–1510, 1990
Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME et al.: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48–53, 1990
Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulinlike growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63: 2139–2147, 1989
Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor 1 and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343–1347, 1988
Peyrat JP, Bonneterre J, Beauscart R, Dijane J, Demaille A: Insulin-like growth factor I receptors (IGF1-R) in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48: 6429–6433, 1988
Ursin G, Longnecker MP, Haile RW: A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiol 6: 137–141, 1995
Le Marchand LL, Kolonel LN, Earle ME, Mi MP: Body size at different periods of adult life and breast cancer risk. Am J Epidemiol 128: 137–152, 1988
Moller DE, Flier JS: Insulin resistance-mechanisms, syndromes and implications. N Engl J Med 325: 938–948, 1991
Zimmet PZ, Collins VR, Dowse GK, Alberti KG: The relation of physical activity to cardiovascular disease risk factors in Mauritians. Mauritius Noncommunicable Disease Study Group. Am J Epidemiol 134: 862–875, 1991
Reitman JS, Vasquez B, Klimes Z et al.: Improvement of glucose homeostasis after exercise training in non-insulin dependent diabetes. Diabetes Care 7: 434–441, 1984
Steiner G: Hyperinsulinaemia and hypertriglyceridemia. J Intern Med 736 (Suppl): 23–26, 1994
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C et al.: Plasma insulin-like growth factor-1(IGF-1) concentrations in human breast cancer. Eur J Cancer 29A: 492–497, 1993
Bruning PF, Vandoorn J, Bonfrer JMG, Van Noord PAH, Korse CM, Linders TC et al.: Insulin-like growth factorbinding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 62: 266–270, 1995
Baxter RC, Martin JL: Regulation and actions of insulinlike growth factor binding protein-3. Adv Exp Med Biol 293: 125–131, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Giudice, M.E., Fantus, I.G., Ezzat, S. et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47, 111–120 (1998). https://doi.org/10.1023/A:1005831013718
Issue Date:
DOI: https://doi.org/10.1023/A:1005831013718